Department of Cardiology, Kurume University Medical Center, Kurume, Japan.
Hypertens Res. 2017 Aug;40(8):721-729. doi: 10.1038/hr.2017.55. Epub 2017 Apr 27.
Hypertension aggravates macrovascular and microvascular diseases and mortality in patients with type 2 diabetes mellitus (T2DM). The current Japanese Society of Hypertension Guidelines of the Management of Hypertension (JSH 2014) recommends that antihypertensive medication should be initiated concomitantly with lifestyle modification when blood pressure (BP) is ⩾130/80 mm Hg and that target levels of office and home BP should be <130/80 mm Hg and <125/75 mm Hg, respectively, in T2DM patients. Considering more favorable metabolic profiles and renoprotective effects than other classes of antihypertensive agents, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are recommended as the first-line therapy for patients with hypertension and T2DM in JSH 2014. However, the target BP and the first-line therapy remain controversial because of the paucity of high-quality evidence with consistency. It is suggested that BP management should be tailored for each patient with T2DM, based on tolerability and considerations of comorbidity.
高血压会加重 2 型糖尿病(T2DM)患者的大血管和微血管疾病及死亡率。日本高血压学会 2014 年版高血压管理指南(JSH 2014)建议,当血压(BP) ⩾130/80mmHg 时,应同时进行生活方式改变和降压药物治疗,T2DM 患者的诊室和家庭 BP 目标值应分别<130/80mmHg 和<125/75mmHg。考虑到代谢谱更优和肾脏保护作用优于其他降压药物,血管紧张素转换酶抑制剂和血管紧张素Ⅱ受体阻滞剂被推荐为 JSH 2014 中高血压合并 T2DM 患者的一线治疗药物。然而,由于高质量证据的一致性不足,目标 BP 和一线治疗仍存在争议。建议根据 T2DM 患者的耐受性和合并症情况,为每位患者量身定制 BP 管理方案。